Core Viewpoint - Valneva SE is actively participating in the 26th World Vaccine Congress, showcasing its advancements in vaccine development, particularly for chikungunya, and engaging with partners in the industry [1][5]. Group 1: Company Participation and Events - Valneva will be represented by its CEO Thomas Lingelbach and senior executives at the World Vaccine Congress from March 31 to April 2, 2026 [1]. - On April 1, 2026, Susanne Eder-Lingelbach will present updates on chikungunya vaccine development, focusing on Phase IV and real-world evidence studies [2]. - Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in a panel discussion on chikungunya and mosquito-borne vaccines on the same day [4]. Group 2: Chikungunya Vaccine Campaign - Valneva and Instituto Butantan have launched a pilot vaccination campaign for the chikungunya vaccine IXCHIQ® in Brazil, with over 12,000 individuals vaccinated to assess the vaccine's effectiveness and safety in real-world conditions [3]. Group 3: Chikungunya Overview - Chikungunya virus (CHIKV) is a mosquito-borne disease causing significant health issues, with over 3.7 million cases reported in the Americas from 2013 to 2023 [6]. - The World Health Organization (WHO) has identified chikungunya as a major public health concern, with its impact expected to grow due to climate change [6]. Group 4: Company Background - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7]. - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8].

Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [6] - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's vaccine pipeline includes candidates for Lyme disease, Zika virus, and other global public health threats, with revenues from its commercial business supporting ongoing development [6] Chikungunya Vaccine Update - The UK’s Commission on Human Medicines (CHM) has updated its recommendations for Valneva's single-dose chikungunya vaccine, IXCHIQ, following a review of its benefits and risks [1] - The updated prescribing information includes restrictions for individuals over 60 years of age and those with specified health conditions, as well as guidelines on vaccination timing prior to travel [2] - The benefit-risk profile of IXCHIQ remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection without contraindicated medical conditions [2][3] Safety Monitoring and Regulatory Actions - The update follows a temporary suspension of IXCHIQ's use in older individuals due to reports of serious adverse events primarily among elderly patients with significant underlying health conditions during a vaccination campaign [3] - Valneva is committed to maintaining high safety standards and will continue to monitor post-marketing safety data for IXCHIQ, collaborating with relevant authorities for potential updates to recommendations [4] Chikungunya Virus Context - Chikungunya virus (CHIKV) is a mosquito-borne disease causing severe joint pain, fever, and other symptoms, with significant global outbreaks since 2004 [5] - Over 3.7 million cases were reported in the Americas between 2013 and 2023, with the economic impact considered substantial, expected to grow due to climate change affecting mosquito distribution [5] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, highlighting the need for effective vaccine solutions [5]